Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT

EBV-associated post-transplant lymphoproliferative disease (PTLD) remains an important complication of allogeneic haematopoietic stem cell transplantation (allo-HSCT). We retrospectively analysed the incidence and risk factors for EBV reactivation in 186 adult patients undergoing consecutive allo-HS...

Full description

Bibliographic Details
Main Authors: Burns, D M, Rana, S, Martin, E, Nagra, S, Ward, J, Osman, H, Bell, A I, Moss, P, Russell, N H, Craddock, C F, Fox, C P, Chaganti, S
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880046/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880046/

Similar Items